Background: Cardiac resynchronization therapy (CRT) is indicated in symptomatic
| INTRODUCTION
Heart failure (HF) is a highly symptomatic syndrome and remains a common cause of poor quality of life, frequent hospitalization and high mortality. Major clinical trials have demonstrated the benefit of cardiac resynchronization therapy (CRT) with a defibrillator (CRT-D) or pacemaker (CRT-P) in terms of clinical outcomes, HF and/or mortality in patients with mild-to-severe symptomatic HF with prolonged QRS width and left ventricular ejection fraction (LVEF) <35% under OMT. CRT has been shown to reduce mortality, morbidity, and improve quality of life in these patients with a life expectancy exceeding 1 year. [1] [2] [3] [4] [5] [6] [7] Optimal medical therapy (OMT) consists of 3 neurohormonal antagonist drugs (angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin II receptor blockers [ARBs] , beta-blockers [BB] , and mineralocorticoid receptor antagonist [MRAs] ) that have been shown to improve survival, reduce hospitalizations for HF, and improve symptoms. [7] [8] [9] [10] [11] [12] [13] [14] Nowadays, ACEIs/ARBs, BBs, and MRAs are cornerstones of HF, and they have class I recommendations in clinical guidelines. 7 However, patients may occasionally exhibit side effects or comorbidity conditions with ACEIs/ARBs, BBs, and MRAs; and uptitration of neurohormonal blockers to guideline-recommended doses is not possible.
The addition of CRT should be considered in patients who remain symptomatic despite optimal pharmacological treatment. Our understanding of the benefits of CRT is incomplete, however it has been shown to reduce mortality and HF hospitalizations, symptoms and improve reverse remodeling and quality of life. Up until now, it has been impossible to assess the prognostic impact of CRT in patients without OMT at the time of implant. Here, we evaluate the long-term outcomes of CRT in patients who were not on OMT at the time of implant. and prolonged QRS duration (≥120 ms) at the time of implantation.
| ME TH ODS
They received pharmacological treatment for HF up-titrated to the maximal tolerated doses according to the European Society of Cardiology guidelines 7 for the management of HF at the discretion of the treating cardiologist.
We registered the baseline characteristics of all of the patients:
age, gender, NYHA functional class, atrial fibrillation, underlying heart disease, pharmacological therapy, glomerular filtration rate, and hemoglobin. Electrocardiographic parameters included QRS width and morphology. Echocardiographic parameters included LV end-diastolic (LVEDV) and end-systolic volume (LVESV), LVEF, and left atrial diameter (LAD). The patients were followed up in the Heart Failure Clinic every 3 or 6 months and in the CRT-Device Clinic every 6 months. Electrocardiogram and echocardiogram were also performed at the 6-month and 2-year follow-ups and according to the discretion of the HF cardiologist. Treating cardiologists followed a specified protocol to achieve OMT. Patients with decreases in LVESV exceeding 15% and/or improvements in LVEF of more than 5% were considered to be echocardiographic responders. Patients with improvements in 1 category in NYHA functional class were considered to be clinical responders. Optimal medical therapy was defined as treatment with ACEIs/ARBs, BBs, and
MRAs.
The study satisfied all of the requirements of local ethics committees and complied with the Declaration of Helsinki.
| Statistical analysis
Continuous variables are expressed as mean ± standard deviation (SD). Categorical data are presented as numbers and percentages.
We used the Mann-Whitney and the Kruskal-Wallis tests to compare continuous numerical variables among the groups. The cumulative probability of death and/or HF was calculated using the KaplanMeier method. We used the multivariate Cox proportional hazards model to estimate the hazard ratio (HR) and 95% confidence interval (95% CI). We carried out statistical analyses in R using the package "survival," which is freely available at http://cran.r-project.org.
| RESULTS

| Patient characteristics
The study population included 328 patients (253 men and 75 women; mean age: 70.2 ± 9.5 years) who were consecutively implanted with a CRT device at our institution. The mean follow-up duration was 4.2 ± 2.9 years. Of the 328 patients, 122 (37.2%) were on OMT at baseline. The baseline characteristics are listed in 
| Up-titration of neurohormonal blockers. OMT in follow-up
Up-titration in neurohormonal blockers 1 year after CRT implantation was evaluated. 35 patients died in the first year, and they were OMT groups; the anterior location was more frequent in the nobasal-OMT group, and the posterior location was more frequent in the basal OMT group. However, these differences are not observed after the optimization of pharmacological treatment. Table 2 lists the baseline characteristics and changes according to the treatment in the first year of follow-up.
In the Cox hazards proportion model for death or HF, and death and HF separately, OMT after 1 year of follow-up was an independent predictor of events (Table 3 and Figure 2 ). In fact, patients without OMT had a higher risk of death or HF than patients with OMT at the 1-year follow-up (HR 1.72, 95% CI 1.07-2.78, Figure 2 ).
| DISCUSSION
The primary finding of this follow-up study is that patients with no OMT at baseline who had CRT implanted experienced the same clinical outcomes of HF/death compared with patients on OMT at baseline. Furthermore, those patients who achieved OMT at the 1-year follow-up after implantation had a lower risk of HF/death than patients who remained on no-OMT. This study suggests, for the first time, that CRT may promote medical treatment optimization early after implantation and that this optimization is associated with a better outcome.
Combined treatment with OMT and biventricular pacing has been shown to invoke marked reduction in HF/death events, which appear very early and are sustained. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] This benefit has been observed in patients with mild-to-severe HF symptoms in randomized studies. hypotension, which inhibits up-titrating to the maximum tolerated evidence-based doses. [7] [8] [9] [10] [11] [12] [13] [14] In the REVERSE study, only 35% of patients were on the target dose of BBs, and 60% were receiving 50% of the target dose. 6 Achieving the target doses of neurohormonal treatment has clinical relevance; Schmidt et al 17 showed that the use of higher dosages of neurohormonal blockers was associated with reduction of morbidity and mortality after CRT implantation.
These authors also demonstrated that super-responders were treated with higher doses of ACEIs/ARBs or BBs. Our results suggest that achieving OMT early after CRT implantation had a prognostic value for reducing death and/or HF hospitalizations; and efforts to achieve OMT necessary. Cardiac resynchronization therapy implantation may help optimize pharmacological treatment during the followup period. Such a situation should be recommended as a target in patients with no OMT at the time of implant.
The basal pharmacological treatment in large-scale clinical trials-COMPANION, 2 CARE-HF, 3 MADIT-CRT 4 and RAFT 5 -was as follows: 95%, 90%, 77%, and 96%, respectively, with ACEIs/ARBs; 73%, 68%, 93%, and 90%, respectively, with BBs; 54%, 55%, 32% and 42%, respectively, with MRAs. In our series, the percentage of patients on pharmacological treatment prior to CRT was similar (ACEIs or ARBs: 86%, BBs: 83%, MRAs: 47%) to the percentages observed in the large clinical trials. Triple-pharmacological treatment was achieved in 122 patients (37%) at baseline and improved up to 198 patients (60%) 1 year after CRT implantation.
Thus far, scientific attention has largely focused on refining preimplantation patient selection to predict a favorable response to CRT because 30% of patients do not benefit from CRT. Optimization of preimplant HF pharmacological treatment has been considered to be a measure of response of CRT. 18 However, we have shown that the optimization of pharmacological treatment during the first year of follow-up was associated with a relative risk reduction of HF/ F I G U R E 1 Cumulative survival free of death, heart failure or heart failure and optimal medical therapy at baseline ALVAREZ-ALVAREZ ET AL.
death, which suggests a complementary effect of CRT and up-titration of pharmacological therapy. The reason for this improvement might be that CRT provides acute hemodynamic improvement, [19] [20] [21] [22] with an increase in cardiac output and a reduction in pulmonary capillary wedge and improvement in the mechanical activation sequence. Cardiac resynchronization therapy also supports systemic blood pressure and heart rate, enabling an increase in the doses of drugs without the associated risk of lethal bradycardia and T A B L E 2 Differences in baseline characteristics and clinical, electrical, and echocardiographic variables between patients on basal and 1-year of follow-up optimal medical therapy, optimal medical therapy only at 1-year of follow-up and no-optimal medical therapy hypotension. So, in CARE-HF, 3 25% of patients had a resting rate of ≤60 beats per minute at baseline; CRT could prevent symptoms of bradycardia in addition to the benefit of resynchronization. Up-titration of neurohormonal treatment after CRT has been described in other studies with consistent findings. A small study reported a major reduction in hospitalizations and mortality with increasing dosages of ACEIs/ARBs after CRT. 23 Mullens et al 24 The selection of the optimal candidates for CRT is critical, but the presence of baseline OMT might not be an exclusion criterion. It is clinically important to recognize patients who might tolerate uptitration of neurohormonal blockers after CRT implantation because this subgroup of patients exhibits better outcomes.
| LIMITATIONS
This investigation was a retrospective study conducted at a single center. As a consequence, the patient sample size was limited.
Adjustment of pharmacological treatment was at the discretion of the HF team. However, these aspects are inherent to any real-world analyses. Therefore, our results need to be confirmed in future large, multicenter trials.
| CONCLUSION
In this follow-up study, basal OMT prior to CRT implant was not associated with a better outcome. Optimal medical therapy achieved at the 1-year follow-up was associated with a reduced risk of HF/ death compared with no-OMT patients. Our results suggest that efforts should be made to achieve medical treatment optimization after CRT implantation to improve outcomes.
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